Original language | English (US) |
---|---|
Article number | 285 |
Journal | Signal Transduction and Targeted Therapy |
Volume | 7 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2022 |
ASJC Scopus subject areas
- Genetics
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Signal Transduction and Targeted Therapy, Vol. 7, No. 1, 285, 12.2022.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes
AU - Liu, Yang
AU - Liu, Jianying
AU - Zou, Jing
AU - Kalveram, Birte
AU - Machado, Rafael R.G.
AU - Ren, Ping
AU - Türeli, Sina
AU - Smith, Derek J.
AU - Weaver, Scott C.
AU - Xie, Xuping
AU - Shi, Pei-Yong
N1 - Funding Information: We thank Phillip R. Dormitzer for his helpful discussions during the study. We thank Sam Wilks, Barbara Mühlemann, and Eric LeGresley for discussions on Antigenic Cartography. P.-Y.S. was supported by NIH grants HHSN272201600013C, U01AI151801 and UL1TR001439, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation. S.C.W. was supported by NIH grant R24 AI120942. P.R. and X.X. were partially supported by the Sealy & Smith Foundation. J.L. was supported by James W. McLaughlin Fellowship Fund. S.T. and D.J.S. were supported by the NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program. Funding Information: We thank Phillip R. Dormitzer for his helpful discussions during the study. We thank Sam Wilks, Barbara Mühlemann, and Eric LeGresley for discussions on Antigenic Cartography. P.-Y.S. was supported by NIH grants HHSN272201600013C, U01AI151801 and UL1TR001439, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation. S.C.W. was supported by NIH grant R24 AI120942. P.R. and X.X. were partially supported by the Sealy & Smith Foundation. J.L. was supported by James W. McLaughlin Fellowship Fund. S.T. and D.J.S. were supported by the NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program.
PY - 2022/12
Y1 - 2022/12
UR - http://www.scopus.com/inward/record.url?scp=85135961431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135961431&partnerID=8YFLogxK
U2 - 10.1038/s41392-022-01137-1
DO - 10.1038/s41392-022-01137-1
M3 - Letter
C2 - 35963863
AN - SCOPUS:85135961431
SN - 2095-9907
VL - 7
JO - Signal Transduction and Targeted Therapy
JF - Signal Transduction and Targeted Therapy
IS - 1
M1 - 285
ER -